Newm-035 -

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook

: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown. NEWM-035

The drug was developed by , a spinoff from Kyoto University, led by Dr. Katsu Takahashi. : Success in Phase I will lead to

If clinical trials continue to show success, researchers aim to make TRG-035 commercially available by . This would offer a biological alternative to traditional prosthetic solutions like dental implants, bridges, or dentures. Japan Begins Human Trials for Tooth Regrowth Drug TRG-035 The drug was developed by , a spinoff